title: Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.
abstract: The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.
authors: Department of Infection, Immunity and Biochemistry, The School of Medicine, Cardiff University, Cardiff, United Kingdom.
authors: Simon A
authors: SA
authors: Jones
authors: Jürgen
authors: J
authors: Scheller
authors: Stefan
authors: S
authors: Rose-John
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology; D050822:Cytokine Receptor gp130 / Q000276:immunology*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D015850:Interleukin-6 / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology; D019947:Receptors, Interleukin-6 / Q000235:genetics / Q000276:immunology*; D015398:Signal Transduction / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D050822:Cytokine Receptor gp130; C502936:tocilizumab